UNSPSC 51334407: Fenimide

This classification denotes an antipsychotic agent with the molecular formula C13H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z48G09KOD, chemically known as 2,5-pyrrolidinedione, 4-ethyl-3-methyl-3-phenyl- but generally known as fenimide, which bears US NIH Compound Identifier 6068. European Medicines Agency schedules Fenimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07565MIG. The term FENIMIDE is an International Non-Proprietary Name.

UNSPSC 51334407 Fenimide is a Commodity code whose recent state and local activity does not align with its nominal scope. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems for community health delivery, a pharmaceutical and medical-device procurement unrelated to fenimide, a thermoplastic resin used in industrial composites and high-temperature applications. The mismatch suggests either a tagging error in the source data or a fundamental disconnect between the code's intended use and how at least one jurisdiction has classified the purchase. State and local procurement offices do not routinely source fenimide for community health or opioid-response programs, which are the actual drivers of recent activity under this code number.

Seminole County, Florida represents the only identifiable issuing body in recent records under this code. The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to its Community Health Building in Sanford, with an IFB response deadline of July 26, 2023, and a two-year initial term plus one-year renewal option. Vendors must include all shipping and delivery costs in their bids, maintain specified insurance coverage, and comply with E-Verify requirements and federal regulations, with potential FEMA funding contingencies. The code shows no material activity across other states or jurisdictions, and no recent opportunities genuinely aligned with fenimide procurement have emerged in state and local channels.